The National Quality Forum  (NQF) is a not-for-profit, nonpartisan, membership-based organization that works to catalyze improvements in healthcare. NQF endorsement is the gold standard for healthcare quality. NQF-endorsed measures are evidence-based and scientifically acceptable (i.e., reliable and valid), and in tandem with the delivery of care and payment reform. Additionally, the CMS relies on the guidance of NQF to foster the use of a more uniform set of measures across federal programs that provide health coverage for about 120 million Americans.

ASCO continues to receive endorsement from NQF for nine quality measures. Each measure is evaluated by NQF for suitability on (1) importance, (2) scientific acceptability, (3) feasibility, (4) usability, and (5) related and competing measures. The ASCO measures are endorsed for the accountability designation.  Accountability measures are suitable for public reporting, payment incentive programs, and the selection of providers by consumers, health plans, or purchasers. The quality improvement designation indicates measure use for internal monitoring of performance within an organization or group so that analyses and subsequent remedial actions can be taken.

ASCO Measures Endorsed by NQF

NQF Number  Measure Title 
210 Percentage of Patients who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life
213 Percentage of Patients who Died from Cancer Admitted to the ICU in the Last 30 Days of Life
216 Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days 
0383 Oncology: Medical and Radiation – Pain Intensity Quantified (paired with 0384)
0384 Oncology: Medical and Radiation– Pain Intensity Quantified (paired with 0383)
0384e Oncology: Medical and Radiation– Pain Intensity Quantified
1858 Appropriate Treatment for Patients with Stage I (T1c)-III HER2 Positive Breast Cancer 
1859 KRAS/NRAS Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
1860 Patients with Metastatic Colorectal Cancer and KRAS/NRAS Gene Mutation Spared Treatment with anti-Epidermal Growth Factor Receptor Monoclonal Antibodies